Patient Blood Management Market Background

Patient Blood Management Market

Patient Blood Management Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033

Modified Date : Nov 2026
Format :PDFWordExcel
No. of Pages : 300
Industry : Healthcare IT

What Is Driving the Patient Blood Management Market Outlook?

The global patient blood management market size is expected to be valued at US$ 16.59 billion in 2026 and projected to reach US$ 25.61 billion by 2033, growing at a CAGR of 6.4% between 2026 and 2033.

Between 2020 and 2025, the market grew at a CAGR of about 5.5%, as elective surgeries recovered after pandemic delays and hospitals faced repeated blood supply shortages. Three factors now drive growth: health authorities promoting patient blood management as a standard of care, rising surgical and trauma volumes in aging populations, and wider use of point-of-care coagulation testing and cell salvage. The market is moving from simply supplying blood toward an evidence-based approach that treats anemia, reduces blood loss, and limits unnecessary transfusions. Software that tracks transfusion decisions and outcomes is becoming central to hospital programs.

Key Report Takeaways

  • By Product: Instruments held 40.0% share in 2026, while Software is projected to expand at a 10.3% CAGR through 2033, driven by hospital transfusion monitoring and clinical decision support.
  • By Component: Whole Blood & Red Blood Cells held 59.6% share in 2026, while Plasma is projected to expand at a 9.3% CAGR through 2033, driven by targeted coagulation therapy in trauma and surgery.
  • By Application: Preoperative Anemia Management held 36.8% share in 2026, while Acute Blood Loss Management is projected to expand at an 8.6% CAGR through 2033, driven by trauma, obstetric hemorrhage, and cardiac surgery protocols.
  • By End User: Hospitals held 50.0% share in 2026, while Diagnostic Clinics & Pathology Labs are projected to expand at an 8.2% CAGR through 2033, driven by outpatient anemia screening and coagulation testing.
  • By Region: North America held 35.2% share in 2026, while Asia Pacific is projected to expand at an 8.4% CAGR through 2033, driven by rising surgical volumes in China and India.

Global Patient Blood Management Market Trends and Insights

Drivers Impact Analysis

Two drivers carry the strongest influence on patient blood management demand during the forecast period.

Driver Impact on CAGR Forecast Geographic Relevance Impact Timeline
WHO guidance and national PBM programs High Europe, North America, Asia Pacific Medium term (2-4 years)
Rising surgical volumes and blood supply pressures High Global Long term (≥4 years)

WHO Guidance and National Programs Are Driving Patient Blood Management Adoption

Guidance from the World Health Organization and national programs are the strongest drivers of patient blood management adoption. Hospitals invest in anemia clinics, testing equipment, cell salvage, and software when health authorities define these as standards of care.

The mechanism is policy backed by clinical evidence. In 2021, the World Health Organization issued a policy brief calling patient blood management an urgent priority, and in March 2025, it released implementation guidance for national and hospital programs. The guidance covers identifying and treating anemia, reducing blood loss, and improving blood clotting. Western Australia’s statewide program reported about 41% fewer red blood cell units transfused alongside lower mortality and costs. Countries such as Germany, Spain, the Netherlands, and Australia have built national programs. Accreditation standards from the Association for the Advancement of Blood & Biotherapies encourage hospitals to formalize transfusion management, which raises demand for products.

Rising Surgical Volumes and Blood Shortages Are Expanding Patient Blood Management Demand

Rising surgical volumes and recurring blood shortages are expanding patient blood management demand. Hospitals must conserve donated blood while performing more complex operations on older patients with anemia and chronic disease.

The cause is a growing gap between transfusion demand and donor supply. Aging populations need more cardiac, orthopedic, cancer, and vascular surgery, which often involve significant blood loss. At the same time, the eligible donor pool is shrinking in many countries. In January 2024, the American Red Cross declared an emergency blood shortage after its national supply dropped sharply. Blood shortages delay surgeries and raise costs. Intraoperative cell salvage recovers a patient’s own blood during surgery and returns it, reducing dependence on donors. Antifibrinolytic drugs, minimally invasive surgery, and point-of-care coagulation testing also limit blood loss. These pressures make blood conservation an operational priority for hospitals.

Restraints Impact Analysis

Two restraints limit how quickly patient blood management programs expand.

Restraint Impact on CAGR Forecast Geographic Relevance Impact Timeline
Upfront program costs and limited reimbursement Medium Global, strongest in emerging markets Medium term (2-4 years)
Clinical inertia and lack of trained coordinators Medium Global Medium term (2-4 years)

Upfront Costs and Weak Reimbursement Limit Patient Blood Management Programs

Upfront costs and weak reimbursement limit patient blood management program adoption. Hospitals must invest in equipment, staff, and software before seeing savings, and these savings often appear in other budgets.

The specific cost sources are capital equipment, disposables, and dedicated personnel. Cell salvage machines, viscoelastic coagulation analyzers such as TEG and ROTEM, and transfusion management software require significant purchase or lease costs. Each procedure uses single-use processing sets and test cartridges. Programs also need coordinators, anemia clinics, and intravenous iron infusions. Many payers do not reimburse anemia management or viscoelastic testing separately, so hospitals must justify spending through reduced blood purchases and shorter stays. In emerging markets in Asia Pacific, Latin America, and Africa, low blood prices and limited budgets make these investments harder to justify.

Clinical Inertia and Skills Gaps Slow Patient Blood Management Implementation

Clinical inertia and skills gaps slow patient blood management implementation in hospitals. Even where evidence and guidance exist, transfusion practices often vary widely between surgeons, anesthesiologists, and departments.

The underlying causes are habit, fragmented responsibility, and limited training. Many clinicians learned to transfuse based on fixed hemoglobin thresholds rather than individual patient needs. Patient blood management requires coordination among surgeons, anesthesiologists, hematologists, laboratory staff, and nurses, but no single department may own the program. Preoperative anemia screening needs referral pathways weeks before surgery, which many hospitals lack. Medical education often gives little attention to blood management. Without dedicated coordinators, executive sponsors, and audit data, programs often stall after initial enthusiasm. These gaps limit adoption beyond leading academic and teaching centers and reduce the use of products that support evidence-based practice.

Market Opportunities

Transfusion Decision Support Software Opens a High-Growth Digital Revenue Pool

Transfusion decision support software opens a high-growth digital revenue pool in patient blood management. Hospitals need tools that guide clinicians toward appropriate transfusions and measure program performance.

Software vendors and device makers with informatics platforms can capture this demand. Clinical decision support embedded in electronic health records prompts clinicians when transfusion orders fall outside guidelines. Dashboards track blood use by surgeon, procedure, and department, helping hospitals benchmark and improve. Analytics also identify patients with preoperative anemia who need treatment before surgery. Integration with blood bank systems and laboratory results improves accuracy. Hospital quality teams, transfusion committees, blood bank directors, and multi-hospital health systems are the main customers. Vendors can also sell benchmarking services across hospital networks. Subscription pricing creates recurring revenue, while proven reductions in blood use and complications help vendors justify adoption.

Obstetric and Trauma Bleeding Management Creates a Point-of-Care Revenue Pool

Obstetric and trauma bleeding management creates a point-of-care revenue pool for patient blood management suppliers. Postpartum hemorrhage and traumatic injuries cause many preventable deaths worldwide, and rapid coagulation assessment guides targeted treatment.

Companies offering fast viscoelastic testing, cell salvage, and coagulation factor concentrates can capture this demand. In October 2025, HemoSonics received FDA clearance to use its Quantra hemostasis system in peripartum obstetric procedures, described as the first cleared viscoelastic platform for obstetric bleeding. The World Health Organization promotes bundles for postpartum hemorrhage treatment. Trauma centers, maternity units, cardiac surgery departments, and military medical services are the main customers. Point-of-care results in minutes help clinicians give the right blood products instead of fixed ratios. Expanded clinical indications open new hospital departments to bleeding management products.

Segment Analysis

By Product: Instruments Lead While Software Gains Momentum

Instruments held 40.0% share in 2026. Cell salvage systems, blood warmers, apheresis machines, coagulation analyzers, and blood bank equipment are essential for blood conservation and transfusion. Products from Haemonetics, LivaNova, Fresenius Kabi, Terumo, and Werfen are widely installed in hospitals.

Software is the fastest-growing product type, expanding at a 10.3% CAGR through 2033. Hospitals use transfusion management software, clinical decision support, and analytics dashboards to track blood use and guide clinicians. Integration with electronic health records helps identify anemic patients and inappropriate transfusion orders. Regulators and accreditation bodies increasingly expect hospitals to monitor transfusion outcomes. Accessories and consumables generate recurring revenue for installed instruments. For the market, software growth supports a shift from product sales toward data-driven programs that demonstrate clinical and financial value.

By Component: Whole Blood & Red Blood Cells Lead While Plasma Grows Fastest

Whole Blood & Red Blood Cells held 59.6% share in 2026. Red cells are the most commonly transfused blood component, used for anemia, surgery, trauma, and cancer treatment. Collection, processing, storage, and compatibility testing generate large demand for related products.

Plasma is the fastest-growing component, expanding at a 9.3% CAGR through 2033. Targeted coagulation management increasingly uses plasma and plasma-derived factor concentrates to correct specific clotting problems. Viscoelastic testing helps clinicians decide when plasma or fibrinogen concentrates are needed. Massive transfusion protocols in trauma and obstetrics also use plasma early. Pathogen reduction technology improves plasma safety. Platelets remain important for cancer and surgical patients. For the market, plasma growth reflects a shift toward precise, goal-directed hemostatic therapy instead of fixed transfusion ratios.

By Application: Preoperative Anemia Management Leads While Acute Blood Loss Management Grows Fastest

Preoperative Anemia Management held 36.8% share in 2026. Many surgical patients have untreated anemia, which raises transfusion and complication risks. Screening and treatment with intravenous iron, nutrition, and other therapies before surgery is a core pillar of patient blood management.

Acute Blood Loss Management is the fastest-growing application, expanding at an 8.6% CAGR through 2033. Trauma centers, cardiac surgery units, and maternity wards need rapid tools to control bleeding. Point-of-care coagulation testing, cell salvage, antifibrinolytics, and factor concentrates reduce blood loss and guide targeted therapy. New clearances for obstetric bleeding expand use. Intraoperative blood conservation and postoperative care remain important applications. For the market, acute bleeding growth increases demand for fast, high-value testing and recovery systems.

By End User: Hospitals Lead While Diagnostic Clinics & Pathology Labs Grow Fastest

Hospitals held 50.0% share in 2026. Surgery, trauma, intensive care, and cancer treatment occur mainly in hospitals, which run blood banks, transfusion services, and blood management programs. Large hospitals invest in cell salvage, coagulation analyzers, and software.

Diagnostic Clinics & Pathology Labs are the fastest-growing end user, expanding at an 8.2% CAGR through 2033. Outpatient anemia screening before surgery, iron studies, and coagulation testing are increasingly performed outside hospitals. Laboratories also support blood typing and compatibility testing for regional hospitals. Growth in outpatient surgery shifts preoperative testing to clinics. Blood banks and ambulatory surgical centers remain important users. For the market, outpatient growth expands demand for diagnostic tests and supports earlier anemia treatment before patients arrive for surgery.

Geography Analysis

Which Region Is Leading the Patient Blood Management Market?

North America is leading the patient blood management market with a 35.2% share in 2026. The United States performs a very large number of surgeries, has advanced hospital infrastructure, and hosts leading suppliers such as Haemonetics. The Association for the Advancement of Blood & Biotherapies offers patient blood management standards and accreditation. Repeated blood shortages have pushed hospitals to conserve blood. Viscoelastic testing is widely used in trauma and cardiac surgery centers. Canada has provincial blood conservation programs. One change shaping the region is the growth of outpatient surgery, which shifts anemia screening earlier in the care pathway.

Europe Leads Patient Blood Management Policy Through National Programs

Europe is a major patient blood management market with strong policy leadership. Germany runs a large national patient blood management network, and Spain, the Netherlands, Austria, and Switzerland have well-established programs. The European Commission has supported guides for implementing patient blood management in hospitals. Werfen in Spain supplies ROTEM coagulation testing, while Fresenius Kabi and B. Braun in Germany provide blood management products. Public health systems favor programs that reduce blood purchasing costs, hospital stays, and complications, and many hospitals now publish transfusion audit results. One opportunity is expanding preoperative anemia clinics in Poland, Czechia, and other countries with developing programs.

Which Region Is Growing Fastest in the Patient Blood Management Market?

Asia Pacific is growing fastest in the patient blood management market at an 8.4% CAGR through 2033. China and India are expanding hospital capacity and surgical volumes, while facing blood supply shortages and high anemia rates. Japan has a rapidly aging population with rising surgical needs, and Terumo and Asahi Kasei are major regional suppliers. Australia is a global leader in patient blood management, with national guidelines and the Western Australia program as a model. Limited clinician awareness, weak reimbursement, and few trained coordinators remain barriers. One opportunity is anemia screening programs for women, older adults, and surgical patients.

Latin America Develops Patient Blood Management Amid Blood Supply Shortages

Latin America is an emerging patient blood management market where blood supply shortages and rising surgical demand drive interest. Brazil and Mexico have large public and private hospital networks and growing private healthcare sectors that invest in blood conservation. Colombia, Argentina, and Chile have academic centers piloting hospital-wide programs. Key barriers include limited funding, low reimbursement, reliance on family replacement donors, and few trained program coordinators. Anemia is common among women and children in many countries, raising transfusion needs during childbirth and surgery. One opportunity is cell salvage and coagulation testing in private hospitals performing cardiac and orthopedic surgery.

Middle East & Africa Adopts Patient Blood Management to Protect Scarce Blood Supplies

Middle East & Africa is a developing market where scarce blood supplies make patient blood management valuable. Saudi Arabia and the United Arab Emirates are investing in advanced hospitals and quality programs, including blood conservation. In Africa, chronic blood shortages, high anemia rates, and maternal hemorrhage make blood management critical. South Africa has the region’s most developed blood services through the South African National Blood Service, and teaching hospitals there run blood conservation initiatives. Key barriers include limited funding, infrastructure gaps, unreliable cold chains, and few specialists outside major cities. One opportunity is maternal hemorrhage programs supported by international health organizations.

Competitive Landscape

The patient blood management market is moderately concentrated. Haemonetics, Terumo, Fresenius Kabi, Grifols, LivaNova, and Werfen hold strong positions in cell salvage, apheresis, coagulation testing, and blood products. Medtronic, B. Braun, Immucor, Bio-Rad Laboratories, Abbott, and Roche compete in devices, blood bank diagnostics, and laboratory testing. Specialist firms such as HemoSonics focus on point-of-care coagulation testing.

Companies compete on clinical evidence, speed of results, ease of use, integration with hospital systems, consumable costs, and service support. Hospitals prefer suppliers that provide clinical training, education, and program support, not just products. Software and analytics increasingly differentiate supplier offerings because hospitals must prove savings and outcomes. Portfolio focus is also changing as companies concentrate on higher-growth hospital segments and exit lower-margin blood collection products.

Strategic moves show how competition is changing. In January 2025, Haemonetics completed the sale of its whole blood collection and processing portfolio to GVS, sharpening its focus on hospital and plasma businesses. In March 2025, the World Health Organization released implementation guidance for patient blood management, encouraging national adoption. In October 2025, HemoSonics gained FDA clearance for Quantra use in obstetric bleeding. These moves show competition shifting toward point-of-care testing and hospital-focused blood management solutions.

Three themes shape vendor strategy. First, companies are expanding clinical indications for testing. Second, they are adding software, analytics, and program services. Third, they are focusing portfolios on high-growth hospital segments.

Patient Blood Management Market Industry Leaders

  • Haemonetics
  • Terumo
  • Fresenius Kabi
  • Grifols
  • Werfen

Recent Industry Developments

October 2025: HemoSonics received FDA clearance for Quantra use in peripartum obstetric procedures - opens obstetric bleeding management.

March 2025: The World Health Organization released implementation guidance on patient blood management - supports national program adoption.

January 2025: Haemonetics completed the sale of its whole blood portfolio to GVS - focuses resources on hospital and plasma businesses.

Patient Blood Management Market Report Scope

Metric Value
Study Period 2020-2033
Market Size 2026 US$ 16.59 Billion
Market Size 2033 US$ 25.61 Billion
CAGR 2026-2033 6.4%
Absolute Dollar Opportunity US$ 9.02 Billion
Largest Market North America
Fastest-Growing Market Asia Pacific
Market Concentration Medium
Major Players Haemonetics, Terumo, Fresenius Kabi, Grifols, Werfen

This report covers products and solutions used in patient blood management, including instruments such as cell salvage systems and coagulation analyzers, accessories and consumables, and software for transfusion management, across whole blood, red cells, plasma, and platelets. It excludes therapeutic drugs such as intravenous iron and plasma-derived medicines sold separately. The base year is 2025, and the forecast period runs from 2026 to 2033. All values are expressed in US$ Billion.

Patient Blood Management Market Segmentation

Product

  • Instruments
  • Accessories & Consumables
  • Software

Component

  • Whole Blood & Red Blood Cells
  • Plasma
  • Platelets

Application

  • Preoperative Anemia Management
  • Intraoperative Blood Conservation
  • Acute Blood Loss Management
  • Postoperative Care

End User

  • Hospitals
  • Diagnostic Clinics & Pathology Labs
  • Blood Banks
  • Ambulatory Surgical Centers

Regions

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Our Research Methodology

Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.

View Methodology
Quality Assured

Quality Assured

Rigorous Validation Process

Confidentiality Assured

Confidentiality Assured

End-to-end Data Security

Custom Research Services

Custom Research Services

Tailored To Your Objectives

FAQs

The patient blood management market is valued at US$ 16.59 billion in 2026, led by instruments used in hospitals for blood conservation.

The market is projected to reach US$ 25.61 billion by 2033, growing at a 6.4% CAGR and adding US$ 9.02 billion.

Software is growing fastest at a 10.3% CAGR through 2033, driven by hospital transfusion monitoring and clinical decision support tools.

Asia Pacific is growing fastest at an 8.4% CAGR through 2033, driven by rising surgical volumes and blood shortages in China and India.

North America holds the largest share at 35.2% in 2026, supported by high surgical volumes, advanced hospitals, and accreditation standards.

Related Reports